Download PDF
Horm Metab Res 2011; 43(7): 464-469
DOI: 10.1055/s-0031-1277226
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

Aldosterone Perturbs Adiponectin and PAI-1 Expression and Secretion in 3T3-L1 Adipocytes

P. Li1 , 2 , [*] , X.-N. Zhang2 , [*] , C.-M. Pan2 , F. Sun2 , D.-L. Zhu1 , H.-D. Song2 , M.-D. Chen2
  • 1Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, P. R. China
  • 2Ruijin Hospital, Shanghai Institute of Endocrinology, State Key Laboratory of Medical Genomics, Molecular Medicine Center, Shanghai Jiao Tong University (SJTU) School of Medicine, P. R. China
Further Information

Publication History

received 20.02.2011

accepted 19.04.2011

Publication Date:
10 June 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Aldosterone is considered as a new cardiovascular risk factor that plays an important role in metabolic syndrome; however, the underlying mechanism of these effects is not clear. Hypoadiponectinemia and elevated circulating concentration of plasminogen activator inhibitor-1 (PAI-1) are causally associated with obesity-related insulin resistance and cardiovascular disease. The aim of the present study is to investigate the effect of aldosterone on the production of adiponectin and PAI-1 in 3T3-L1 adipocytes. Northern and Western blot analyses revealed that aldosterone treatment inhibited adiponectin mRNA expression and secretion and simultaneously enhanced PAI-1 mRNA expression and secretion in a time- and dose-dependent manner. Rosiglitazone did not prevent aldosterone's effect on adiponectin or PAI-1 expression. In contrast, tumor necrosis factor (TNF)-α produced dramatic synergistic effects on adiponectin and PAI-1 expression when added together with aldosterone. Furthermore, the effects of aldosterone on adiponectin and PAI-1 expression appear to be mediated through glucocorticoid receptor (GR) but not mineralocorticoid receptor (MR). These results suggest that the effects of aldosterone on adiponectin and PAI-1 production are one of the underlying mechanisms linking it to insulin resistance, metabolic syndrome and cardiovascular disease.

Key words

adipose tissue - adipocytokines - insulin resistance - metabolic syndrome

References

  • 1 Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action.  Heart Fail Rev. 2006;  10 7-13
    Google Scholar
  • 2 Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?.  Hypertension. 2008;  51 1252-1258
    Google Scholar
  • 3 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.  J Clin Endocrinol Metab. 2006;  91 454-459
    Google Scholar
  • 4 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function.  Endocr Rev. 2008;  29 133-154
    Google Scholar
  • 5 Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor.  Trends Endocrinol Metab. 2005;  16 104-107
    Google Scholar
  • 6 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome.  Nature. 2006;  144 881-887
    Google Scholar
  • 7 Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS)1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes.  Endocrinology. 2009;  150 1662-1669
    Google Scholar
  • 8 Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.  Cardiovasc Res. 2009;  84 164-172
    Google Scholar
  • 9 Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines.  Circulation. 2008;  117 2253-2261
    Google Scholar
  • 10 Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Kazuyuki T. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.  J Clin Invest. 2006;  116 1784-1792
    Google Scholar
  • 11 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences.  Arterioscler Thromb Vasc Biol. 2006;  26 2200-2207
    Google Scholar
  • 12 Li RY, Song HD, Shi WJ, Hu SM, Yang YS, Tang JF, Chen MD, Chen JL. Galanin inhibits leptin expression and secretion in rat adipose tissue and 3T3-L1 adipocytes.  J Mol Endocrinol. 2004;  33 11-19
    Google Scholar
  • 13 Yuan GY, Chen X, Ma QY, Qiao J, Li RY, Li XS, Li SX, Tang JF, Zhou LB, Song HD, Chen MD. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes.  J Endocrinol. 2007;  194 275-281
    Google Scholar
  • 14 Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y. Aldosterone and TGF-β1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.  Am J Physiol Renal Physiol. 2008;  294 F1287-F1295
    Google Scholar
  • 15 Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes A potential pathogenetic link between obesity and cardiovascular disease.  Circulation. 1996;  93 106-110
    Google Scholar
  • 16 Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.  Br J Pharmacol. 2008;  153 636-645
    Google Scholar
  • 17 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura L, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-2099
    Google Scholar
  • 18 Hong HK, Cho YM, Park KH, Lee CT, Lee HK, Park KS. Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells.  Diabetes Res Clin Pract. 2003;  62 1-8
    Google Scholar
  • 19 Cawthorn WP, Sethi JK. TNF-α and adipocyte biology.  FEBS Lett. 2008;  582 117-131
    Google Scholar
  • 20 Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.  Am J Med. 2003;  115 S62-S68
    Google Scholar
  • 21 Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.  J Intern Med. 2005;  257 167-175
    Google Scholar
  • 22 Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study.  Hypertension. 2007;  49 1455-1461
    Google Scholar
  • 23 Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification.  Circulation. 2005;  111 747-753
    Google Scholar
  • 24 Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.  Nat Med. 1996;  2 800-803
    Google Scholar
  • 25 Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes.  Mol Cell Endocrinol. 2005;  239 55-61
    Google Scholar
  • 26 Urbanet R, Pilon C, Calcagno A, Peschechera A, Hubert EL, Giacchetti G, Gomez-Sanchez C, Mulatero P, Toffanin M, Sonino N, Zennaro MC, Giorgino F, Vettor R, Fallo F. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism.  J Clin Endocrinol Metab. 2010;  95 4037-4042
    Google Scholar
  • 27 He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.  Horm Metab Res. 2003;  35 18-23
    Google Scholar
  • 28 Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade.  Endocr J. 2004;  51 243-251
    Google Scholar
  • 29 Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.  Science. 1987;  237 268-275
    Google Scholar
  • 30 Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J. The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses.  J Endocrinol. 2010;  204 153-164
    Google Scholar
  • 31 Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotension II in insulin resistance: an update.  Clin Endocrinol (Oxf). 2009;  71 1-6
    Google Scholar

1 These authors contributed equally to this work.

Correspondence

H.-D. Song
M.-D. Chen

Ruijin Hospital

Shanghai Institute of

Endocrinology

State Key Laboratory of Medical

Genomics

Molecular Medicine Center

Shanghai Jiao Tong University

(SJTU) School of Medicine

Ruijin Road 2

Shanghai 200025

P. R. China

Phone: + 86/21/6431 55 87

Fax: + 86/21/6467 36 39

Email: huaidong_s1966@163.com

Email: mingdaochensh@yahoo.com

      >